Tag Archives: Keytruda
Dr. Jack West: Why the Broader FDA Approval of First Pembrolizumab Monotherapy based on KEYNOTE-042 is an Invitation to Inferior Care in Advanced NSCLC
Weighing the clinical significance of new clinical trial results with immunotherapy in stage III and IV NSCLC
Dr. David Spigel, Part 2: Identifying the Optimal Duration for Immunotherapy in Responding Patients with Advanced Lung Cancer
Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)
Dr. Jack West summarizes his list of the top 5 most influential trials in lung cancer that reported results in 2018, including why they matter. (13:27)
Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)
Dr. Jack West summarizes new information presented at ESMO 2018 on the PePS2 trial of pembrolizumab (Keytruda) in patients with advanced NSCLC performance status (PS) of 2, which demonstrated favorable efficacy and no concerning challenges with toxicity in this population. (4:12)
Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066)
Dr. Jack West reviews longitudinal outcomes for patients on the KEYNOTE-010 trial of pembrolizumab (Keytruda) vs. docetaxel as 2nd line therapy for advanced NSCLC, with helpful new info on those completing 2 years of pembro & implications for practice. (8:03)
Immunotherapy with Pembrolizumab in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-055)
Dr. Daniel Goldstein summarizes key data in genitourinary oncology from ASCO 2018, including new results on pembrolizumab (Keytruda) for metastatic prostate cancer, asking whether it could find a place as treatment for a subset of these patients. (2:17)
Pembrolizumab in First Line Clear Cell RCC & the Evolving Role of Immunotherapy in Metastatic RCC: Highlights from ASCO 2018 (BMIC-053)
Dr. Daniel Goldstein discusses the results of a trial of first line pembrolizumab (Keytruda) as first line therapy for patients with metastatic clear cell renal cell carcinoma and the implications for the future role of immunotherapy in RCC. (3:18)
Could Immunotherapy Replace Neoadjuvant Chemo for Muscle-Invasive Transitional Cell Carcinoma? Highlights from ASCO 2018 (BMIC-047)
Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including important studies evaluating the efficacy of neoadjuvant immunotherapy instead of chemotherapy for muscle-invasive transitional cell carcinoma of the bladder? (3:34)